Stoke Therapeutics, Inc. (STOK) research
Stoke Therapeutics, Inc.- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $25.29
- As of
Stoke Therapeutics, Inc. (STOK): 4 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 10-Q filed 2026-08-03.
As of . Source: SEC EDGAR filings for STOK. Method and limitations.
Share the STOK intelligence card
See STOK live in the terminal
Track STOK's insider trades, 13F flows, options positioning, and cross asset confluence as they update, on one live board. Free account.
Open the live STOK terminal, freeActive signals for STOK
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +5105% to STOK (2026Q2)
- mediumNEW_POSITION
TWO SIGMA INVESTMENTS, LP new position in STOK
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +5105% to STOK (2026Q2)
- mediumNEW_POSITION
TWO SIGMA INVESTMENTS, LP new position in STOK
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +5105% to STOK (2026Q2)
FREE, NO ACCOUNT
Every signal on STOK, as it fires
You are seeing 5 of 13 signals recorded on STOK since 2026-05-24.
The five above landed across 2 days. The other 8 were recorded on 3 other days. 8 of the 13 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in STOK (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| CITADEL ADVISORS LLCCUSIP 86150R107 · 2026Q2 | $16M | 0.00% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP 86150R107 · 2026Q2 | $8.5M | 0.00% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 86150R107 · 2026Q2 | $2M | 0.00% | , |
| D. E. Shaw & Co., Inc.CUSIP 86150R107 · 2026Q2 | $1.9M | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, STOK
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
STOK against its peers
STOK's operating margin of -11.2% ranks in the 74th percentile of 16 Biotechnology sub-industry peers, fiscal periods ending between 2025-06-30 and 2025-12-31.
| Metric | STOK | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 184M USD | 74.7M USD | 72 | 15 |
| Operating margin | -11.2% | -145.0% | 74 | 16 |
| Net margin | -3.7% | -106.4% | 81 | 17 |
| Return on equity | -2.0% | -35.1% | 88 | 20 |
Peers (22): BHVN, SEPN, LKFT, ABSI, ZYME, NTLA, TYRA, XNCR, NBTX, GHRS, RXRX, VIR, MESO, TSHA, AGIO, IMCR, NVAX, ADMA, RAPP, FBRX, ANAB, SNDX. Left out: KARD (no annual filing), KLRA (no annual filing), COAG (no annual filing). Fiscal periods ending between 2025-06-30 and 2025-12-31. Every figure is one full fiscal year read from one annual filing (STOK: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
See more STOK signals as they fire
Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to STOKand get the insider, 13F, options, and confluence read in one view.